title: Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer.
abstract: Development and progression of colon cancer may be related to cytokines. Cytokines with diagnostic value have been identified individually but have not been implemented into clinical praxis. Using a multiplex protein array, the authors explore a panel of cytokines simultaneously and compared its performance to carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9). Serum concentrations of 12 cytokines were simultaneously determined by multiplex biochip technology in 50 colon cancer patients and 50 healthy controls. Serum levels of interleukin-8 (IL-8) and CEA were significantly higher in cancer patients than in healthy controls. Areas under the receiver operating characteristic curves (AUCs) were largest for IL-8, followed by CEA, vascular endothelial growth factor (VEGF), and CA 19-9. Analyses regarding marker combinations showed an advantage over single marker performance for CEA, VEGF, and CA 19-9 but not for IL-8. Multiplex biochip array technology represents a practical tool in cytokine and cancer research when simultaneous determination of different biomarkers is of interest. The results suggest that the assessment of IL-8, CEA, VEGF, and possibly CA 19-9 serum levels could be useful for colon cancer screening with the potential of also detecting early stage tumors. Further validation studies using these and additional markers on a multiplex array format are encouraged.
authors.affiliation: Laboratory for Surgical Research, Department of Surgery, University of Lübeck, Germany.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Bünger
authors.forename: Ulrike
authors.initials: U
authors.lastname: Haug
authors.forename: Frances Maria
authors.initials: FM
authors.lastname: Kelly
authors.forename: Katja
authors.initials: K
authors.lastname: Klempt-Giessing
authors.forename: Andrew
authors.initials: A
authors.lastname: Cartwright
authors.forename: Nicole
authors.initials: N
authors.lastname: Posorski
authors.forename: Leif
authors.initials: L
authors.lastname: Dibbelt
authors.forename: Stephen Peter
authors.initials: SP
authors.lastname: Fitzgerald
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Bruch
authors.forename: Uwe Johannes
authors.initials: UJ
authors.lastname: Roblick
authors.forename: Ferdinand
authors.initials: F
authors.lastname: von Eggeling
authors.forename: Hermann
authors.initials: H
authors.lastname: Brenner
authors.forename: Jens Karsten
authors.initials: JK
authors.lastname: Habermann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D003110:Colonic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D057166:High-Throughput Screening Assays / Q000592:standards*; D006801:Humans; D016209:Interleukin-8 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D040081:Protein Array Analysis; D012680:Sensitivity and Specificity; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D016209:Interleukin-8; D042461:Vascular Endothelial Growth Factor A